The initiation of coverage by Goldman Sachs, a major financial institution, with a Buy rating indicates a positive outlook for Sagimet Biosciences. The price target of $33 suggests a significant upside potential from the current price. This could lead to increased investor interest and potentially a rise in the stock price in the short term.